High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience.

Autor: Nasr LF; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zoghbi M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Lazcano R; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Nakazawa M; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Bishop AJ; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Farooqi A; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Mitra D; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Guadagnolo BA; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Benjamin R; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Patel S; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ravi V; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Araujo DM; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Livingston A; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zarzour MA; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Conley AP; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ratan R; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Somaiah N; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Lazar AJ; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Roland C; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Keung EZ; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Nassif Haddad EF; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Publikováno v: Cancers [Cancers (Basel)] 2024 May 01; Vol. 16 (9). Date of Electronic Publication: 2024 May 01.

A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma.

Autor: Roland CL; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. clroland@mdanderson.org., Nassif Haddad EF; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Centre Léon-Bérard, University Claude Bernard Lyon I, Lyon, France.; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Keung EZ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang WL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lin H; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chelvanambi M; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Parra ER; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wani K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Guadagnolo BA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bishop AJ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burton EM; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hunt KK; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Torres KE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Feig BW; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Scally CP; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lewis VO; Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bird JE; Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ratan R; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Araujo D; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zarzour MA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel S; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Benjamin R; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Conley AP; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Livingston JA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravi V; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lin PP; Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Moon BS; Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Satcher RL; Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mujtaba B; Department of Musculoskeletal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Witt RG; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Traweek RS; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cope B; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lazcano R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wu CC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhou X; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mohammad MM; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chu RA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Damania A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sahasrabhojane P; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tate T; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Callahan K; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nguyen S; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ingram D; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Morey R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Crosby S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mathew G; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Duncan S; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lima CF; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Blay JY; Centre Léon-Bérard, University Claude Bernard Lyon I, Lyon, France., Fridman WH; Centre de Recherche des Cordeliers, Inserm, Université Paris-Cité, Equipe Labellisée Ligue Contre le Cancer, Paris, France., Shaw K; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wistuba I; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ajami N; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wargo JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Somaiah N; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: Nature cancer [Nat Cancer] 2024 Apr; Vol. 5 (4), pp. 625-641. Date of Electronic Publication: 2024 Feb 13.

Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?

Autor: Thirasastr P; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Sutton TL; Division of Surgical Oncology, OHSU Knight Cancer Institute, Oregon Health & Science University School of Medicine, Portland, OR 97239, USA., Joseph CP; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Lin H; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Amini B; Department of Musculoskeletal Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Mayo SC; Division of Surgical Oncology, OHSU Knight Cancer Institute, Oregon Health & Science University School of Medicine, Portland, OR 97239, USA., Araujo D; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Benjamin RS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Conley AP; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Livingston JA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ludwig J; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Patel S; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ratan R; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ravi V; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zarzour MA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Nassif Haddad EF; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Nakazawa MS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhou X; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Heinrich MC; Cell and Developmental Biology, OHSU Knight Cancer Institute, Oregon Health & Science University School of Medicine, Portland, OR 97239, USA., Somaiah N; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Publikováno v: Cancers [Cancers (Basel)] 2024 Feb 23; Vol. 16 (5). Date of Electronic Publication: 2024 Feb 23.